Merck & Co., Inc. $MRK Shares Sold by GAM Holding AG

GAM Holding AG cut its position in Merck & Co., Inc. (NYSE:MRK) by 1.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,484 shares of the company’s stock after selling 2,403 shares during the period. GAM Holding AG’s holdings in Merck & Co., Inc. were worth $9,775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in MRK. Little House Capital LLC raised its holdings in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after acquiring an additional 308 shares during the period. Semus Wealth Partners LLC raised its holdings in shares of Merck & Co., Inc. by 8.2% during the 1st quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after acquiring an additional 382 shares during the period. Longfellow Investment Management Co. LLC raised its holdings in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after acquiring an additional 3,282 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its holdings in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after acquiring an additional 79,529 shares during the period. Finally, Diversified Trust Co raised its holdings in shares of Merck & Co., Inc. by 3.8% during the 2nd quarter. Diversified Trust Co now owns 189,651 shares of the company’s stock worth $15,013,000 after acquiring an additional 6,930 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 0.3%

Shares of NYSE:MRK opened at $86.30 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a market capitalization of $215.56 billion, a PE ratio of 13.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. The firm’s 50-day moving average is $84.59 and its two-hundred day moving average is $81.75. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.22. The company had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price target on the stock. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Morgan Stanley decreased their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.